D47.Z9, Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissueICD-10-CM
No Prior Auth Required
Covered without prior authorization (high confidence)
CGS-J15-L40386, Erythropoiesis Stimulating Agents (ESA)
J15
CGS-J15-L38070, MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
J15
CGS-J15-L38822, MolDX: Minimal Residual Disease Testing for Cancer
J15
CGS-J15-L34356, Erythropoiesis Stimulating Agents (ESA)
J15
CGS-J18-L34356, Erythropoiesis Stimulating Agents (ESA)
J18
CGS-J18-L38070, MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
J18
CGS-J18-L38822, MolDX: Minimal Residual Disease Testing for Cancer
J18
CGS-J18-L40386, Erythropoiesis Stimulating Agents (ESA)
J18
WPS-J5-L38176, MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
J5
WPS-J5-L39040, MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J5
A59004, Billing and Coding: MolDX: Minimal Residual Disease Testing for Hematologic Cancers
J5
A57878, Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
J5
WPS-J5-L38835, MolDX: Minimal Residual Disease Testing for Cancer
J5
A58756, Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J5
NGS-J6-L40334, Erythropoiesis Stimulating Agents
J6
NGS-J6-L40333, Erythropoiesis Stimulating Agents
J6
NGS-J6-L39297, Off-label Use of Rituximab and Rituximab Biosimilars
J6
NGS-J6-L37606, Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases
J6
NGS-J6-L36850, Peripheral Nerve Blocks
J6
NGS-J6-L35000, Molecular Pathology Procedures
J6
Ask Backwork about documentation requirements, denial risks, or coverage in your state.